Gastroparesis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The market size of Gastroparesis is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, Theravance Biopharma, PTC Therapeutics, GlaxoSmithKline, Targacept Inc., Takeda, Millennium Pharmaceuticals, Inc., Eli Lilly and Company, Evoke Pharma, Ironwood Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Tranzyme, Inc.

[Nevada, United States] - DelveInsight's "Gastroparesis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Gastroparesis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Gastroparesis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Gastroparesis Market Report:
The Gastroparesis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In September, 2024: CinDome Pharma, Inc. announced that the purpose of their clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.
In August, 2024: Vanda Pharmaceuticals announced a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.
In March, 2024: Vanda Pharmaceuticals announced that a trial will take place in order to investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
According to Sato and Grover (2022), in the United States, based on insurance claims database, standardized (to age, sex and geographical region) prevalence of gastroparesis was 267.7 per 100,000 adults, whereas prevalence of definite gastroparesis was much lower at 21.5 per 100,000 persons. On the other hand, in the United Kingdom, standardized prevalence of gastroparesis, as documented in general practice records, was 13.8 per 100,000 persons.
According to International Foundation for Gastrointestinal Disorders, an average of 30% to 50% of patients with gastroparesis have a diagnosis of idiopathic gastroparesis. About 25% of gastroparesis patients are diagnosed with diabetic gastroparesis. This can affect people with either Type 1 or Type 2 diabetes. It also suggests that gastroparesis affects about 38 women and 10 men per 100,000 people.
Key Gastroparesis Companies are as follows: Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, Theravance Biopharma, PTC Therapeutics, GlaxoSmithKline, Targacept Inc., Takeda, Millennium Pharmaceuticals, Inc., Eli Lilly and Company, Evoke Pharma, Ironwood Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Tranzyme, Inc.
Key Gastroparesis Therapies are as follow: Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, CIN-102 Dose 1,2,3, GM-611, GSK962040 (25 mg tablet), TC-6499, NG101, TAK-954 TAK-906 Maleate, tadalafil, Itopride, IW-9179, Prucalopride, TZP-102, metoclopramide, RM-131, Relamorelin.
Launching multiple stage Gastroparesis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Gastroparesis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Gastroparesis Overview:
Gastroparesis is a chronic condition characterized by delayed gastric emptying, where the stomach empties its contents into the small intestine at a slower rate than normal. This impairment in gastric motility can lead to various digestive symptoms and complications. The condition can significantly impact a person's quality of life and may be associated with several underlying causes.

Gastroparesis Drugs Uptake and Pipeline Development Activities:
The drugs uptake section examines the adoption rates of new or upcoming drugs within the study period. It details market uptake for individual drugs, patient adoption of therapies, and the sales performance of each drug. Furthermore, the report offers insights into Gastroparesis Pipeline Development Activities, evaluating therapeutic candidates at different stages and identifying the key companies involved.

For more information about Gastroparesis companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Gastroparesis Therapies and Key Companies:
Tradipitant: Vanda Pharmaceuticals
NG101: Neurogastrx
CIN-102: CinDome Pharma
PCS12852: Processa Pharmaceuticals
velusetrag dose 1: Theravance Biopharma
CNSA-001: PTC Therapeutics
Camicinal: GlaxoSmithKline
CIN-102 Dose 1: CinDome Pharma, Inc.
GM-611: Chugai Pharma USA
GSK962040 (5 mg tablet): GlaxoSmithKline
TC-6499: Targacept Inc.
TAK-954: Takeda

Gastroparesis Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Gastroparesis.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Gastroparesis Epidemiology Segmentation:
The Gastroparesis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Gastroparesis Total Prevalence
Gastroparesis Prevalent Cases by severity
Gastroparesis Gender-specific Prevalence
Gastroparesis Diagnosed Cases of Episodic and Chronic

Gastroparesis Market Drivers:
Increasing prevalence and high unmet need for drugs to treat the disease might help the companies to capture the market and might also help upcoming therapies by providing patient pool for their clinical trials.
The expected launch of potential emerging therapies is anticipated to drive the gastroparesis market.

Gastroparesis Market Barriers:
Available therapies used for the treatment of gastroparesis are majorly symptomatic.
Significant side effects of approved therapies.
Strict pricing and reimbursement policies can further impede thegrowth of the emerging therapies.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Gastroparesis Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Gastroparesis Companies: Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, Theravance Biopharma, PTC Therapeutics, GlaxoSmithKline, Targacept Inc., Takeda, Millennium Pharmaceuticals, Inc., Eli Lilly and Company, Evoke Pharma, Ironwood Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Tranzyme, Inc.
Key Gastroparesis Therapies: Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, Camicinal, CIN-102 Dose 1,2,3, GM-611, GSK962040 (25 mg tablet), TC-6499, NG101, TAK-954 TAK-906 Maleate, tadalafil, Itopride, IW-9179, Prucalopride, TZP-102, metoclopramide, RM-131, Relamorelin.
Gastroparesis Therapeutic Assessment: Current marketed and emerging therapies
Gastroparesis Market Dynamics: Gastroparesis Market drivers and Gastroparesis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Gastroparesis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Gastroparesis market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/gastroparesis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1 Key Insights
2 Report Introduction
3 Executive Summary of Gastroparesis
4 Gastroparesis Market Overview at a Glance
5 Key Events
6 Epidemiology and Market Forecast Methodology
7 Disease Background and Overview
8 Epidemiology and Patient Population
9 Patient Journey
10 Marketed Therapies
11 Emerging Therapies
12 Gastroparesis: Seven Major Market Analysis
13 Unmet Needs
14 SWOT Analysis
15 KOL Views
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.